Opto Circuits (India) Limited

Disclaimer
This presentation does not constitute an offer or invitation to purchase or subscribe for any
securities in any jurisdiction, including the United States. No part of its should form the basis of
or be relied upon in connection with any investment decision or any contract or commitment to
purchase or subscribe for any securities. None of our securities may be offered or sold in the
United States without registration under the U.S. Securities Act of 1933, as amended, except
pursuant to an exemption from registration therefrom. This presentation is confidential and may
not be copied or disseminated, in whole or in part, and in any manner.

This presentation contains forward-looking statements based on the currently held beliefs and
assumptions of our management, which are expressed in good faith and in their opinion
reasonable. Forward-looking statements involve known and unknown risks, uncertainties and
other factors, which may cause our actual results, financial condition or performance or industry
results to differ materially from the results, financial condition or performance expressed or
implied by such forward-looking statements. Given these risks, uncertainties and other factors,
viewers of this presentation are cautioned not to place undue reliance on these forward-looking
statements. We disclaim any obligation to update these forward-looking statements to reflect
future events or developments.
 OCI – An Overview
 Established in 1992, 17 years in an evolving knowledge
intensive medical device industry

 Develop, manufacture and market niche medical device

products in both invasive and non-invasive segments

 Group of 9 companies with a consolidated total income

of Rs. 8,602 million (FY09), headquartered in
Bengaluru, Karnataka, India

 Public limited company listed on NSE and BSE

 OCI – The Company
 Markets - present in US, Europe and India
 Manufacturing - present in India and US
 R&D, Design, Innovation – present in
Germany, US and India
 Intellectual property – owned worldwide
 Talent pool – qualified and experienced
 Customer relationships – established, long-
standing relationships
 Awards & Recognitions
 Business Standard – BS1000 Star SME (March
2009)

 Industry 2.0 – Ranked 11th in the 3rd SMB

Awards (March 2009)

 Forbes Asia – 200 Best Under a Billion in

AsiaPac (September 2008)
 Acquisitions

Criticare
Devon Systems,
& Inc.,
Eurocor USA
Ormed
Altron GMBH India
Industries Germany 2008
Thermometer 2007
India
Division 2006
Monitoring
Unilever 2004
Advanced Division of
Palco labs India
Micronic
USA
Devices 2002
India 2002
2001
 Product Profile

OCIL GROUP

Non Invasive Invasive Others

Patient Monitors Cardiac Services

Pulse Oximeters Drug Eluding

Multi Parameter Monitors Bare Metal

Sensors Balloons

Disposable Peripheral

Reusable
 Industry Overview

 Patient monitoring
 Global market is estimated to grow to US$ 5.7 billion by 2011
(Source: Global Markets Direct, March 2008)
 Major industry players include Phillips, GE Healthcare,
Siemens Medical, Dragger GmbH, Mindray and Space Labs

 Interventional Cardiology
 Global market is estimated to grow to US$ 7.36 billion by
2015 (Source: Global Coronary Stent Market Report, Koncept
Analytics, May 2009)
 Major industry players include Johnson & Johnson (Cordis),
Boston Scientific, Medtronic and Abbott Laboratories
 Product Progression
Peripheral Stenting

BMS with Dilatation Catheter Remote Monitoring

E
DEB
IV

Anesthesia & Respiratory

S

Monitors
VA

DES
IN

Multiparameter monitors
BMS CC
Compatible Sensors
BMS Steel
Brand Sensors

VE
SI
VA
Pulse Oximeters

IN
N
OEM Sensors

O
N
Invasive Devices
 Drug Eluting Balloon

Bare Metal Stent

Drug Eluting Stent Cobalt-Chromium Dilatation Catheter Bare Metal Stent - Steel
Non Invasive Devices
MULTI PARAMETER ANESTHETIC GAS MONITOR REUSABLE SENSORS
MONITOR

PULSE OXYMETER VITAL SIGNS MONITOR DISPOSABLE SENSORS

GAS BENCH
DESKTOP SPO2
Cohesive mix of Revenue Segment
CRITICALCARE
CRITICAL CARE––Non-discretionary
Non-discretionary

Non-Invasive Invasive

Diagnostic/ Therapeutic
Monitoring
products

TERTIARYCARE
TERTIARY CARE––Pricing
PricingStrength
Strength

Twinproduct
Twin productsegments
segmentsdriving
drivingrevenues
revenues
 Selling and Distribution

 Sales in 56 countries across the 4 market segments

relevant to medical device industry, i.e. USA, Europe,
Asia-Pacific & Rest of World

 Domestic and international network consists of

distributors as well as direct sales force in India
(AMDL), Germany (Eurocor) and the United States
(Criticare & Mediaid)

 Consumer reach is through OEMs, Distributors, Group

Purchasing Organizations, Hospitals and Doctors
 Manufacturing & Quality

 Currently OCI and subsidiary products are manufactured in

India and the US
 Details of manufacturing facilities in India:
 Total eight facilities – five facilities at Bengaluru, one in
Chennai, one in Vizag and one at Parwanoo (Himachal
Pradesh)
 Qualitycertifications – five facilities have ISO 9001:2000,
two also have ISO 13485:2003 and one also has ISO
14000:2004 & ISO 18001:2007
 Manufacturing facility at Wisconsin (US) is ISO 13485:2003
Regulation, Approvals and Certification

 Each country has its own regulatory body, although

certain countries accept FDA 510k and/or CE
certification

 We currently have a number of FDA 510k (US FDA)

approvals and CE markings for Europe for most
products in our non-invasive product portfolio

 We have the CE marking for most products in our

invasive product portfolio
 Design and R&D

 Design and development facility at Bonn, Germany, is

ISO 13485 :2003 and CE certified
 Each division is headed by a CEO and has a
Technology Manager who manages R&D
 Local universities are also used for some R&D projects
 OCI R&D division works for subsidiaries and also
works on projects to be marketed by subsidiaries
 R&D spend is equivalent to 12% of the FY09 revenue
 Trade Marks and IPs

 Numerous registered/owned Trade marks and

Intellectual Property Rights

 35 patents and 28 pending patent applications

 29 registered trademarks and 8 pending

trademark applications
 Management
Name Designation
Mr. Vinod Ramnani Chairman & Managing Director
Mrs. Usha Ramnani Executive Director
Mr. Jayesh Patel Promoter Director
Mr. Thomas Dietiker Promoter Director
Dr. Suleman Adam Merchant Director
Dr. Anvay Mulay Director
Mr. Rajkumar Raisinghani Director
Mr. V.Balasubramanian Director
Dr William Walter O’ Neill Director
 Share Holding Pattern
As on 30-06-2009
DETAILS %

Promoters 31.10

Foreign Institutional Investors 22.57

Domestic Institutions 4.03

Non-Institutions 42.30
 Consolidated Financial summary
Amount in
Years Ended Amount in Rs Million US$ mn
March 31st 2007 2008 2009 2009
Sales 2,516 4,681 8,185 161
YOY Growth % 80% 86% 75%
EBITDA 862 1,543 2,878 56
YOY Growth % 83% 79% 87%
PAT 733 1,313 2,093 41
YOY Growth % 90% 79% 59%

Gross Block 607 778 2,660 52

Net Worth 2,125 3,346 5,166 101
Capital employed 2,848 4,442 10,682 210

EBITDA / Sales 34% 33% 35%

PAT/Sales 29% 28% 26%
Financial Updates – Consolidated
Amount in Rs. Millions

Q1 FY2008-09 Q1 FY2009-10

SALES 1774 2303

EBITDA 581 775

PBT 459 596

PAT 450 593

 Investment Rationale
 Growing and evolving medical device industry
 Diverse product portfolio across invasive and
non-invasive segments
 Positioned for future growth backed by strong
brands and proprietary technology
 Experienced management team with a strong
execution track record
 Total Income CAGR of 49% over the last 3 years
(FY07-09)
 Consistent dividend payout record from year 2001